Trial Type: Ovarian Cancer

A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent of Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMatch Treatment Trial

A Phase 1 Study of NM32-2668 (Anti ROR1/Anti CD3/Anti-HSA Tri-Specific Antibody) in Adult Patients with Selected Advanced Solid Tumors

A Phase 2 Multi-Center Open-Label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer

A Phase 1b Study of Combination ATR (M1774) and BET Inhibition (ZEN00-3694) to Exploit ARID1A Loss in Recurrent Ovarian and Endometrial Cancer

A phase 1/2 dose escalation and dose-expansion study of zn-c3 in combination with niraparib and zn-c3 monotherapy in subjects with platinum-resistant ovarian cancer

Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy

Phase I/Ib Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin with Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805

LS-P-Poppy: First-in-class antibody-drug conjugate (ADC) targeting fibronectin (PYX-201) for solid tumors

A phase 1b study of zn-c3 in combination with chemotherapy in patients with platinum-resistant ovarian, peritoneal, or fallopian tube cancer

Detecting cancers Earlier Through Elective plasma-based CancerSEEK Testing – Ascertaining Serial Cancer patients to Enable New Diagnostic II